REVTORPYK (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Breast Cancer, US
Celcuity’s REVTORPYK (gedatolisib) was approved by the US FDA in July 2026 for HR+/HER2- locally advanced or metastatic breast cancer with PIK3CA wild-type, in combination with fulvestrant, with or without palbociclib, after progression on endocrine therapy. VIKTORIA-1 (n=392) showed arm A median PFS 9.3 vs 2.0 months for fulvestrant alone, ORR 32% vs 1%. Commercial launch planned for late Q3 2026.
How this was made
The 30-second read
Why it matters
The FDA approval based on the PIK3CA wild-type cohort of Phase III VIKTORIA-1, plus a late-Q3 2026 commercialization plan and a Q3 2026 sNDA for PIK3CA-mutant disease, creates multiple near-term catalysts for Celcuity and sets up potential label expansion.
Market read
This is a primary regulatory approval with explicit commercialization and follow-on regulatory steps, which can materially change expectations for timing and probability of future revenue.
What to watch
The article does not quantify expected uptake, pricing, reimbursement, or competitive positioning versus existing endocrine plus CDK4/6 standards, which are key drivers of commercialization outcomes.
Background
REVTORPYK (gedatolisib) is a kinase inhibitor targeting class I PI3K isoforms and mTORC1/2, intended for HR+/HER2- locally advanced or metastatic breast cancer without detected PIK3CA mutation, in combination with fulvestrant with or without palbociclib.
Ticker impact
Celcuity’s REVTORPYK (gedatolisib) received FDA approval in July 2026 for HR+/HER2- PIK3CA wild-type breast cancer, with commercial launch planned for late Q3 2026.
Near-term upside bias into late Q3 2026 as traders price commercialization progress and potential sNDA expansion; volatility likely around regulatory and launch execution milestones.
The article provides a primary regulatory event (FDA approval) plus specific commercialization timing and a follow-on sNDA plan, which are actionable catalysts for a biotech. However, it does not include financial guidance, sales expectations, or market reaction data, limiting precision.
Market effects
Strengthens the competitive narrative for PI3K/mTOR pathway targeted therapies in HR+/HER2- breast cancer, potentially increasing attention on similar pathway inhibitors and CDK4/6 combination strategies.
US regulatory approval can accelerate US adoption and influence global partner/regulator discussions for subsequent filings.
If the sNDA and other-territory marketing authorizations proceed, it could broaden the addressable market for gedatolisib internationally and affect global treatment sequencing debates.
Counterpoint
Approval in a biomarker-defined PIK3CA wild-type cohort may limit near-term addressable sales versus broader populations, and launch execution risk could temper the stock reaction.
Key entities
- drugREVTORPYK (gedatolisib)
FDA-approved PI3K/mTOR pathway inhibitor for HR+/HER2- PIK3CA wild-type breast cancer in combination with fulvestrant, with or without palbociclib.
- companyCelcuity
Developer of gedatolisib, planning commercial launch late Q3 2026 and an sNDA filing in Q3 2026 for PIK3CA-mutant disease.
- clinical_trialVIKTORIA-1 (NCT05501886)
Phase III trial whose PIK3CA wild-type cohort supported FDA approval; compared REVTORPYK plus fulvestrant (with or without palbociclib) versus fulvestrant alone.
